Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Id vs Rd Maintenance in Multiple Myeloma
NCT05477797Recruiting
- Sponsor
- Renji Hospital
- Start
- Feb 2023
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ixazomib in multiple myeloma (MM) (2 arms), sponsored by Renji Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Feb 2023; status: recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05477797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477797.